18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.
Background: While CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body 18F-fluoroestradiol (18F-FE...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 53; no. 1; pp. 374 - 389 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Dec2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |